J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara

 
• By Joseph Haas

A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.

A money bill drawn on a chalk board looking like a growth graph with an upwards pointing arrow symbolizing economic relationships.
J&J reported continued strong growth for Stelara, Tremfya

More from Earnings

More from Business